Melbourne, Australia;  Starpharma Holdings Ltd (ASX:SPL;OTCQX: SPHRY) today provided an update on the developments within its substantial drug delivery program.

 Key Points: 

• Dendrimer-docetaxel program advancing rapidly; clinical trial expected to commence in 2013
• Successful application of dendrimers to a number of important classes of drugs including small molecules, antibodies and proteins
• Analysis shows Starpharma’s dendrimers applicable to more than 50% of top-selling pharmaceuticals - highlighting versatility and potential to develop improved formulations

Read More